Breast Cancer

, Volume 16, Issue 4, pp 295–300 | Cite as

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

  • Yutaka Tokuda
  • Yasuhiro Suzuki
  • Yuki Saito
  • Shinobu Umemura
Special Feature New strategy for HER-2 testing and trastuzumab therapy

Abstract

Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.

Keywords

Metastatic breast cancer HER2-positive Trastuzumab 

References

  1. 1.
    Ohta M, Tokuda Y, Suzuki Y, Kubota M, Watanabe T, Fujii H, et al. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody. Jpn J Clin Oncol. 2001;31:553–6.PubMedCrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network (NCCN). http://www.nccn.org/professionals/physician_gls/default.asp.
  3. 3.
    Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10:2435–46.PubMedGoogle Scholar
  4. 4.
    Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702–8.PubMedGoogle Scholar
  5. 5.
    Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006; abstract 3.Google Scholar
  6. 6.
    Nakagami K, Inoue K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Ohashi Y, Sano M, Noguchi S. Randomized Phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2008; abstract 3132.Google Scholar
  7. 7.
    Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen CH, Ebert A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer. 2004;40:988–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol. 2002;21:55a. abstract.Google Scholar
  12. 12.
    Cortes J, Dicosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II Study. Clin Cancer Res. 2009;15:307–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs. 1997;15:219–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Tokuda Y, Umemura S, Saito Y, Suzuki Y. Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in HER2 positive human cancer xenografts in athymic mice. J Clin Oncol. 2008;26:abstract 14641.Google Scholar
  15. 15.
    Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Bontenbal M, Seynaeve C, Stouthard J, Bos M, Braun H, Erdkamp FL, et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study). J Clin Oncol. 2008;26:44s. abstract 1014.CrossRefGoogle Scholar
  17. 17.
    Hayes D. Systemic therapy for HER2-positive metastatic breast cancer. UpToDate version 16.3.Google Scholar
  18. 18.
    Burstein HJ, Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom PK, et al. Trastuzumab and vinorelbine or taxane chemotherapy for HER2 + metastatic breast cancer: the TRAVIOTA study. J Clin Oncol. 2006;24:18s. abstract 650.CrossRefGoogle Scholar
  19. 19.
    Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Amer Assoc Cancer Res. 2005;46:abstract 5062.Google Scholar
  20. 20.
    Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol. 2008;26:47s. abstract 1025.Google Scholar
  21. 21.
    O’Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26:44s. abstract 1015.CrossRefGoogle Scholar
  22. 22.
    Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, et al. In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody against c-erbB-2 product. Br J Cancer. 1996;73:1362–5.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Yutaka Tokuda
    • 1
  • Yasuhiro Suzuki
    • 1
  • Yuki Saito
    • 1
  • Shinobu Umemura
    • 2
  1. 1.Department of Breast and Endocrine SurgeryTokai University School of MedicineIseharaJapan
  2. 2.Department of PathologyTokai University School of MedicineIseharaJapan

Personalised recommendations